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Abstract
The microtubule-dependent molecular motor KIF23 (Kinesin family member 23) is one of two components of the
centralspindlin complex assembled during late stages of mitosis. Formation of this complex is known as an essential step for
cytokinesis. Here, we identified KIF23 as a new transcriptional target gene of the tumor suppressor protein p53. We showed
that p53 reduces expression of KIF23 on the mRNA as well as the protein level in different cell types. Promoter reporter
assays revealed that this repression results from downregulation of KIF23 promoter activity. CDK inhibitor p21WAF1/CIP1 was
shown to be necessary to mediate p53-dependent repression. Furthermore, we identified the highly conserved cell cycle
genes homology region (CHR) in the KIF23 promoter to be strictly required for p53-dependent repression as well as for cell
cycle-dependent expression of KIF23. Cell cycle- and p53-dependent regulation of KIF23 appeared to be controlled by
differential binding of DREAM and MMB complexes to the CHR element. With this study, we describe a new mechanism for
transcriptional regulation of KIF23. Considering the strongly supporting function of KIF23 in cytokinesis, its p53-dependent
repression may contribute to the prevention of uncontrolled cell growth.
Citation: Fischer M, Grundke I, Sohr S, Quaas M, Hoffmann S, et al. (2013) p53 and Cell Cycle Dependent Transcription of kinesin family member 23 (KIF23) Is
Controlled Via a CHR Promoter Element Bound by DREAM and MMB Complexes. PLoS ONE 8(5): e63187. doi:10.1371/journal.pone.0063187
Editor: Sumitra Deb, Virginia Commonwealth University, United States of America
Received January 15, 2013; Accepted March 28, 2013; Published May 1, 2013
Copyright:  2013 Fischer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MQ is recipient of graduate fellowship awarded by the Freistaat Sachsen, SS was supported by a junior research grant and IG was the recipient of thesis
support grant awarded by the Medical School at the University of Leipzig. This work was supported by grants from the Fonds der Chemische Industrie and the
Forschungsausschuss of the Saarland University (to KR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: karen.rother@uks.eu
¤ Current address: Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
. These authors contributed equally to this work.
Introduction
Cell division is a fundamental process, which has to be regulated
very precisely. This control is achieved by utilizing several
mechanisms affecting diverse cell cycle checkpoints. One of the
last possibilities to stop cell division is the regulation of cytokinesis.
During late anaphase the central region of the microtubule spindle
(central spindle) reorganizes to produce the midzone - a tightly
packed bundle of antiparallel microtubules [1]. It is known that
centralspindlin, a heterotetramer composed of two molecules of
Kinesin family member 23 (KIF23) and two molecules of
RACGAP1 is critical for this microtubule bundling during
cytokinesis [2,3]. KIF23 is a kinesin-like motor protein which
can cross-bridge antiparallel microtubules and drive microtubule
movement in vitro [4]. It was found to be a nuclear protein that
localizes to the interzone of mitotic spindles, acting as a plus-end-
directed motor enzyme that moves antiparallel microtubules
in vitro [5].
In accordance with its essential function in cytokinesis,
expression of KIF23 is regulated in a cell cycle-dependent
manner. KIF23 expression is repressed in G0/G1 phase, induced
in early S phase and peaks in G2/M phase [6]. Genes transcribed
differentially during the cell cycle are often controlled through a
cell cycle-dependent element (CDE) and/or a cell cycle genes
homology region (CHR) in their promoters (reviewed in reference
[7]). Interestingly, Seguin et al. identified a functional CHR
element close to the transcription start site of the KIF23 promoter
and demonstrated that this site is involved in promoter repression
of KIF23 in G1 [6]. However, the exact mechanism, particularly
the proteins involved, of KIF23 cell cycle-dependent expression
remains to be elucidated.
For a long time, identification of specific CHR binding proteins
had been elusive. Recently, experimental data together with
bioinformatic analyses suggest that many genes holding phyloge-
netically conserved CHR elements in their promoters binds a
multiprotein complex called DREAM [8]. This complex was first
identified in cells of Drosophila melanogaster and consists of the
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drosophila Rbf, E2f2/Dp and Myb-interacting proteins mip120,
mip130 and mip40. It was determined to be essential for silencing
of developmentally regulated genes [9]. Later the corresponding
mammalian DREAM complex (DP, Rb-like, E2F4 and MuvB)
was discovered [10,11]. The MuvB core of this complex consists of
LIN9, LIN37, LIN52, LIN54 and RBBP4 and is able to recruit
E2F4/DP1 or E2F5/DP1 and RB-like proteins p130 or p107. The
DREAM complex binds to promoters in G0 and early G1 and
serves to repress transcription [10]. When cells progress through
the cell cycle, B-Myb (MYBL2) interacts with the MuvB core and
replaces RB-like proteins (p107/RBL1 and p130/RBL2), E2F4
and DP1/2 to form the activating MMB (Myb-MuvB) complex
[8,10–14]. Very recently, Mu¨ller et al. could demonstrate that
both, the DREAM complex and the MMB complex can directly
bind to the conserved CHR sites of human and mouse cyclin B2
and mouse Ube2c promoters [8].
Using global expression profiling strategies many cell cycle
regulatory genes have been shown to be regulated by the tumor
suppressor protein p53. Induced by a myriad of different stress
signals, which include amongst others DNA damage [15], hypoxia
[16] and oncogenic stimuli [17], p53 protects the integrity of the
genome either by inducing cell cycle arrest or provoking apoptosis.
When activated, p53 mainly acts as a transcription factor. While
cell cycle inhibitors (e.g. p21WAF1/CIP1) were transactivated by p53
[18], expression of many proteins supporting cell cycle progression
and proliferation is shown to be repressed in a p53-dependent
manner [19]. Various mechanisms are described for p53-
dependent repression (reviewed in reference [20]), including direct
DNA binding of p53 [21], interaction with other transcription
cofactors [22] or with the basal transcription machinery [23],
regulation of chromatin structure and promoter methylation
[24,25] or indirect mechanisms. The target gene p21WAF1/CIP1 is
of special importance for p53-dependent gene repression. It has
been implicated in the repression mechanism of several genes.
Furthermore, E2F binding sites in the promoters were implicated
in this regulation [26–28]. Additionally, p21WAF1/CIP1 is sufficient
to cause repression of those genes even in the absence of p53 [26].
However, most of these reports failed to identify E2F sites
responsive to p53 and p21WAF1/CIP1. Interestingly, a large portion
of genes down-regulated by p53 is also expressed in a cell cycle-
dependent manner controlled by CDE/CHR elements in their
promoters which were recently correlated to DREAM binding
[7,8]. Very recently, we could demonstrate that p53 can repress
human and mouse cyclin B2 genes indirectly through a conserved
CHR element [29].
In this report, we identify the gene for the microtubule-
dependent molecular motor protein KIF23 as a new p53 target.
Reduced expression of both splice variants of KIF23 is demon-
strated on mRNA and protein level after wild-type p53 induction.
Furthermore, we show that p53-dependent repression requires
p21WAF1/CIP1 expression and an intact CHR element close to the
transcription start site of the KIF23 promoter. We reveal a cell
cycle-dependent switch from DREAM to MMB complex binding
to the CHR and demonstrate a p53-dependent accumulation of
the DREAM complex at the KIF23 promoter.
Materials and Methods
Cell Culture, Synchronization and Drug Treatment
Parental human colon carcinoma HCT116 cells and HCT116
cells with targeted deletions in both p53 (HCT116 p532/2) or
p21WAF1/CIP1 (HCT116 p212/2) alleles [30] as well as tet-off
inducible DLD-1 cell lines carrying p53wt (D53wt) or p53R175H
(D53mut) transgenes [31] were generously provided by Bert
Vogelstein. D53wt/mut cells were cultured as described previously
[32]. Induced p53 protein expression is achieved by doxycycline
removal. Cells were harvested 9 h after p53 induction.
HCT116 cells, NIH3T3 mouse fibroblasts (DSMZ, Braunsch-
weig, Germany), HFF human foreskin fibroblasts (ATCC,
Manassas, VA, USA) and T98G human glioblastoma cells
(ATCC) were grown in DMEM (Lonza, Basel, Switzerland)
supplemented with 10% fetal calf serum (FCS, Lonza) and
penicillin/streptomycin and maintained at 37 uC and 10% CO2.
HFF, NIH3T3 and T98G cells were synchronized in G0 by
serum deprivation for 48 h, 60 h and 72 h, respectively. Cells
were restimulated for cell cycle re-entry with 20% FCS in DMEM
and collected at given time points. Cell cycle distribution was
checked by FACS analysis.
Doxorubicin was used at a final concentration of 0.2 mg/ml for
48 or 72 h. The Mdm-2 inhibitor nutlin-3 (Cayman Chemical,
Ann Arbor, MI, USA; 10 mM in DMSO) was applied at a final
concentration of 5 mM for 24 h. An appropriate amount of
DMSO served as solvent control for nutlin-3 treatment.
RNA and Protein Extraction, Real-time RT-PCR
Total RNA and protein were isolated using TRIzol Reagent
(Invitrogen, Carlsbad, CA) following the manufacturer’s protocol.
One-step real-time RT-PCR was performed as described previ-
ously [33] employing the LightCycler 2.0 instrument (Roche,
Mannheim, Germany) using the QuantiTect SYBR Green RT-
PCR kit (Qiagen, Hilden, Germany). The following primers were
used for real-time RT-PCR to discriminate between the two splice
variants of KIF23: hKIF23 variant 1_for, 59-CCA TCA CCT
GTG CCT CTT TC-39; hKIF23 variant 1_rev, 59-AAG AGT
AAC CTG CCG CAA TG-39; hKIF23 variant 2_for 59-GTA
GAG TGG CAG CCA AAC AGC-39, hKIF23 variant 2_rev 59-
CTG ATC AGG TTG AAA GAG TAA AGG C-39. Primers
hKIF23 variant 1+2_for 59-TGC TGC CAT GAA GTC AGC
GAG AG-39 and rev 59-CCA GTG GGC GCA CCC TAC AG-
39 detect both splice variants. L7 was used as an endogenous
control employing the primers L7_for 59-GCA CTA TCA CAA
GGA ATA TAG GCA G-39 and L7_rev 59-CCC ATG CAA
TAT ATG GCT CTA C-39.
SDS PAGE and Immunoblot
SDS PAGE and western blot were performed following
standard protocols [33] using antibodies against KIF23 (anti-
MKLP-1 (24), sc-136473, Santa Cruz Biotech, Santa Cruz
Biotechnology, CA, USA, 1:200 dilution), p21WAF1/CIP1 (EA10,
Calbiochem, Merck KGaA, Darmstadt, Germany, 1:500), p53
(DO-1, Calbiochem, 1:2000), GAPDH (G9545, Sigma, 1:500) or
b-actin (AC-15, Sigma, Hamburg, Germany, 1:5000). For
detection of DREAM/MMB complex components, the following
antibodies were applied: E2F4 (C-20, Santa Cruz Biotechnology,
1:750) and p130 (C-20, Santa Cruz Biotech., 1:1000). The B-Myb
LX015.1 monoclonal antibody was generously provided by Roger
Watson [34] and the LIN37 polyclonal antibody was a kind gift
from James A. DeCaprio [10]. Nfya was detected with Nfya (G-2)
monoclonal antibody (Santa Cruz Biotech., 1:2000). For stripping,
the membranes were incubated for 30 minutes in Restore Western
Blot Stripping Buffer (Thermo Scientific, Rockford, IL, USA).
Plasmids and DNA Probes
The human KIF23 promoter (nt 21153 to +1, relative to the
translational start site) was amplified from human genomic DNA
and cloned as KpnI/NcoI fragment into the pGL4.10 firefly-
luciferase reporter-gene vector (Promega, Madison, WI, USA).
Mutation of the CHR element from TTTGAA to TGCATA was
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introduced with the QuikChange site-directed mutagenesis kit
(Agilent Technologies, Santa Clara, CA).
The human p53wt expression plasmid was produced by
amplifying the insert of pCMV-p53wt (kindly provided by Bert
Vogelstein, reference [35]) and cloning in pcDNA3.1HisC
(Invitrogen, Carlsbad, CA, USA). The expression plasmid coding
for p53mut R175H was generated by site-directed mutagenesis.
Expression plasmids for human p21WAF1/CIP1, pCEP-p21wt and
pCEP-p21mut, were generously provided by Bert Vogelstein [18].
DNA probes for affinity purification with a fragment of the
human KIF23 promoter (nt 2296 to +1, relative to the
translational start site) were obtained by PCR using a biotinylated
primer for labeling the 39-end (Invitrogen). As a negative control, a
fragment of the mouse Gapdhs promoter (nt 2169 to +12, relative
to the transcription start site) was used. Sequences of primers can
be obtained upon request.
Transfections and Luciferase Reporter Gene Assays
Transfections of control siRNA (medium GC content, Invitro-
gen) and validated StealthTM p53 siRNA (Invitrogen, VHS40367)
at a final concentration of 100 nM were performed with
DharmaFECT-1 transfection reagent (Dharmacon, Chicago, IL,
USA) at a final dilution of 1:1000 according to the manufacturer’s
instructions [36]. Cells were harvested after 48 hours.
To measure p53- and p21WAF1/CIP1-dependent promoter
activity with luciferase reporter assays, HCT116 cells were plated
in 24-well plates (75,000 cells per well) and transfected by
lipofection with FuGENE 6 (Promega) according to the manufac-
turer’s instructions. Cells were cultured overnight before cotrans-
fection of 250 ng of promoter reporter plasmids along with 25 ng
of constructs expressing wild-type or mutant p53 or p21WAF1/CIP1
proteins and 25 ng of Renilla luciferase plasmid (pGL4.70,
Promega). After 24 h, cells were collected by lysing the cells with
100 ml passive lysis buffer (Promega) per well.
For measuring cell cycle-dependent promoter activity, NIH3T3
cells were plated in 12-well plates (19,000 cells per well). After
24 h, cells were transfected with pGL4 reporter constructs
(transfection mixture per well: 0.2 mg promoter reporter plasmid
(pGL4.10), 0.02 mg Renilla luciferase plasmid (pGL4.70), 1.5 ml
GeneJuice (Merck, Darmstadt, Germany), 60 ml DMEM without
FCS). 24 h after transfection, cells were synchronized by serum
starvation in DMEM without FCS for 60 h. After restimulation
with 20% FCS in DMEM, cells were collected at given time points
by lysing the cells with 200 ml luciferase lysis buffer (Promega) per
well and stored at 280uC.
Luciferase activity was measured with the Dual-Luciferase
Reporter Assay system (Promega) following manufacturer’s
recommendations. Relative light units (RLU) were calculated by
normalizing firefly luciferase activity to Renilla luciferase activity
[8]. pGL4.10 empty vector served as vector control.
DNA-affinity Purification
DNA-affinity purification of protein complexes with density
arrested and asynchronous growing NIH3T3 cells was performed
as described before [8].
Chromatin Immunoprecipitations (ChIPs)
T98G and HCT116 wild-type cells were cross-linked with 1%
formaldehyde for 10 min at room temperature. ChIPs were
performed as described earlier [8]. The following antibodies were
used to precipitate DREAM complex components: E2F4 (C-20,
Santa Cruz Biotech.), p130 (C-20, Santa Cruz Biotech.), B-Myb
(N-19, Santa Cruz Biotech.), p53 (Ab-6, DO-1, Calbiochem),
LIN9 (ab62329, Abcam, Cambridge, UK) and another LIN9
antibody was a kind gift from James A. DeCaprio [10]. A non-
targeting rabbit antibody (IgG, Dako, Glostrup, Denmark) was
used as a control for nonspecific signals. For all precipitations 1 to
2 mg of antibody and 20 to 35 ml of Protein G Dynabead
suspension (Invitrogen) were used. Immunoprecipitated DNA was
used as template for quantitative real-time PCR which was
performed on an ABI 7300 qPCR System (Applied Biosystems,
Forster City, CA) using QuantiTect SYBRGreen PCR Kit
(Qiagen). All PCR results were normalized to input controls.
The following primers were used for qPCR: hKIF23-for 59-TAG
GAG ACA AGC GCC ACT TC-39; hKIF23-rev 59-ACG CTA
AGA GCC CAG GTG A-39; hGAPDHS-for 59-AGA CCA GCC
TGA GCA AAA GA-39; hGAPDHS-rev 59-CTA GGC TGG
AGT GCA GTG GT-39, hp21-for 59-CTG AGC CTC CCT
CCA TCC-39; hp21-rev 59-GAG GTC TCC TGT CTC CTA
CCA TC-39.
FACS Analysis
Cells were fixed for at least 12 h at 4uC in one volume of PBS
with 1 mM EDTA and three volumes of absolute ethanol. DNA
was stained with propidium iodide (Sigma) at a final concentration
of 10 mg/ml in presence of RNase A (10 mg/ml). DNA content per
cell was measured by flow cytometry on a LSR II instrument
(Becton Dickinson, Franklin Lakes, NJ). Data analysis was
performed with WinMDI 2.9 software.
Results
KIF23 mRNA Level is Strongly Reduced after Ectopic
Expression of Wild-type p53
In an indicator DNA microarray hybridization experiment,
which had been performed earlier, using RNA from cells
negative in functional endogenous p53 but stably transfected
with a tet-off system for selective expression of wild-type p53
[37], it was observed that KIF23 mRNA was 14.3-fold
downregulated after ectopic p53wt expression (data not shown).
In order to verify this observation we performed real-time RT-
PCR analyses employing mRNA from the same cell line
(D53wt) comparing KIF23 mRNA levels before and after
induction of wild-type p53 expression. We confirmed the data
from the microarray experiment and found a strong decrease
(6.3-fold) in KIF23 mRNA expression level after wild-type p53
expression (Fig. 1A) which could not be observed in cells
expressing mutant p53 deficient in DNA binding (D53mut)
(Fig. 1A). As demonstrated by FACS analyses, cell cycle
distribution was not altered significantly after induction of p53
mutant expression, but displayed enrichment in G2/M popula-
tion after induction of wild-type p53 expression (Fig. 1C). This
indicates that the expected upregulation of KIF23 expression
resulting from the shift in cell cycle distribution is overcom-
pensated by p53-dependent repression.
Two splice variants are described for human KIF23 [38].
Variant 1 represents the longer form and is also referred to as
CHO1. It contains an additional exon (exon 18), which is
missing in variant 2. So far, no differences in localization,
expression pattern or regulation are known. As exon 18 is
coding for an F-actin interacting domain [38], which may be
essential for special functions of splice variant 1, we were
wondering if mRNA expressions of the two splice variants of
KIF23 were regulated differentially by p53. Employing specific
primers to detect each splice variant of KIF23 separately, we
found essentially the same p53-dependent downregulation of
both mRNAs (Fig. 1B).
Repression of KIF23 by p53
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Stabilization of Endogenous p53 Leads to a Decrease in
KIF23 mRNA Expression
In contrast to overexpression of p53 in the stably transfected
DLD-1 cell line, p53+/+ and p532/2 HCT116 human colon
cancer cells provide an experimental system enabling inducible
endogenous p53 expression at physiological levels. Comparison of
gene regulation in HCT116 p53+/+ cells with that in cells carrying
targeted deletions in both p53 alleles (HCT116 p532/2) allows
direct testing of p53 function in an identical human cellular
background [30]. We determined KIF23 mRNA expression after
stabilization of endogenous p53 in HCT116 cells treated with
doxorubicin or nutlin-3. While the chemotherapeutic agent
doxorubicin leads to stabilization of p53 protein through induction
of posttranslational modifications of p53 by diverse kinases and
acetylases [39], mechanism of nutlin-3 mediated p53-stabilization
differs. Nutlin-3 inhibits interaction of p53 with Mdm2, impeding
its ubiquitination and thereby proteasomal degradation. As shown
in Fig. 1D, KIF23 mRNA levels were drastically downregulated in
HCT116 p53+/+ cells after treatment with doxorubicin for 48 h
(7.7-fold for splice variant 1 and 14,3-fold for splice variant 2,
respectively) as well as after treatment with nutlin-3 for 24 h (5.6-
fold for splice variant 1 and 14,3-fold for splice variant 2,
respectively). Treatment of the isogenic cell line HCT116 p532/
2 with nutlin-3 did not lead to a significant change in KIF23
mRNA expression, while treatment of HCT116 p532/2 cells
with doxorubicin led to a slight increase in KIF23 mRNA
expression (Fig. 1D). Analyses of each KIF23 splice variant
separately revealed nearly identical effects.
Remarkably, treatment of a further isogenic cell line with
targeted disruptions in both p21WAF1/CIP1 alleles (HCT116 p212/
2) with nutlin-3 or doxorubicin did not lead to a decrease in
KIF23 mRNA expression (Fig. 1E), even though two p53 wild-type
alleles were present. Instead, comparable with the effects in p53-
negative HCT116 cells a 2.0-fold increase in KIF23 mRNA
expression after treatment with doxorubicin was observed. FACS
data were obtained to rule out the possibility that KIF23 expression
is solely downregulated as an indirect effect caused by cell cycle
arrest in G1. HCT116 cells show an increase in G2/M cell
population after doxorubicin or nutlin-3 treatment whereas in no
case the G1 cell population was enriched significantly (Fig. 1F). As
expected, cell cycle distribution of HCT116 p532/2 cells after
nutlin-3 treatment did not change considerably (Fig. 1F).
Taken together, these results demonstrate that KIF23 mRNA
expression is strongly repressed by wild-type p53. This effect can
be observed in different cell lines and after different methods of
p53 protein stabilization and seems to be dependent on p21WAF1/
CIP1. Furthermore, p53-dependent repression is true for both
KIF23 splice variants.
p53 Wild-type Reduces KIF23 Protein Expression
We next intended to examine effects of wild-type p53 expression
on KIF23 protein levels. Analyses were carried out in both cell
systems already tested for KIF23 mRNA expression. Induction of
ectopic p53wt expression in D53wt cells led to a significant
decrease in KIF23 protein level while induction of DNA-binding
deficient p53mut expression did not change KIF23 protein
expression (Fig. 2A). Both splice variants of KIF23 are displayed
as a double band in western blot experiments [40]. p53 and
p21WAF1/CIP1 protein levels were analyzed as controls. As
expected, both p53 and p21WAF1/CIP protein expression levels
increased 9 h after induction of ectopic wild-type p53 expression
while no p21WAF1/CIP1 induction was observed in D53mut cells. b-
actin is shown as a loading control (Fig. 2A).
Furthermore, western blot analyses of p53-positive HCT116
wild-type cells demonstrated an apparent loss of KIF23 protein
expression after treatment with doxorubicin for 72 h (Fig. 2B) and
a strong repression after treatment with nutlin-3 for 24 h (Fig. 2C).
However, neither treatment of HCT116 p532/2 nor HCT116
p212/2 cells led to a decrease in KIF23 protein expression
(Figs. 2B and 2C). Consistent with the results of the mRNA
analyses, a slight increase in KIF23 protein expression could be
observed after treatment with doxorubicin (Fig. 2B). Therefore,
the results again indicate that p21WAF1/CIP plays a critical role in
the p53-dependent repression mechanism.
As elevated expression of p53wt led to a downregulation of
KIF23 expression, we next asked if depletion of endogenous basal
p53 reciprocally enhances KIF23 protein expression. To this end,
we performed transient siRNA mediated knockdown of p53 in
HFF cells. The results indicated that even basal levels of p53 are
sufficient to suppress KIF23 expression in human foreskin
fibroblasts. Depletion of endogenous p53 led to a clear increase
in KIF23 protein levels, while expression of p21WAF1/CIP1 is
abolished after treatment with p53-siRNA (Fig. 2D). As a control,
neither KIF23 nor p21WAF1/CIP1 protein levels were affected by
transfection of negative control siRNA.
p53-dependent Downregulation of the KIF23 Promoter
Activity is Mediated through a CHR Element
In order to analyze the mechanism of p53-dependent repression
of KIF23 expression we performed dual luciferase reporter gene
assays employing the 1153bp KIF23 promoter fragment upstream
of the translational start site of the gene (KIF23 Prom -1153/
ATG, Fig. 3A). Promoter activity was quantified in response to
p53 or p21WAF1/CIP1 co-expression in HCT116 p532/2 and
p212/2 cells. As indicated in Figure 3B, wild-type KIF23
promoter activity was 3-fold downregulated by p53 in p53-
negative cells. Remarkably, exclusive expression of p21WAF1/CIP1
in these cells also repressed KIF23 promoter activity by 3.8-fold. In
HCT116 p212/2 cells p21WAF1/CIP1 expression reduced KIF23
promoter activity 4.7-fold, whereas p53wt expression only led to a
1.5-fold decrease in KIF23 promoter activity (Fig. 3B).
In all cases, site-directed mutagenesis of the putative CHR
element found 190 bp upstream of the translational start (Fig. 3A)
abolished repression of KIF23 promoter activity by p53 completely
and left only a marginal CHR-independent repressive effect by
p21WAF1/CIP1 (Fig. 3B).
As tested before, HCT116 cells transfected with p53 or
p21WAF1/CIP1 expression plasmids showed only a slight increase
Figure 1. KIF23 mRNA level is down-regulated by p53. KIF23 mRNA levels were detected semi-quantitatively by real-time RT-PCR. Primers
detecting both splice-variants of KIF23 (variant 1+2) were employed as well as isoform-specific primers. Fold change of KIF23 mRNA expression
relative to not induced or untreated cells is displayed (mean 6 SD, n = 3). (A) In the human colorectal adenocarcinoma cell line DLD-1 carrying tet-off
inducible p53 wild-type (p53wt) or R175H mutant (p53mut) transgenes in a functionally p53-negative background the expression of transgenes was
induced for 9 h. (B) mRNA expression of KIF23 transcript variants in D53wt cells after expression of p53wt was induced for 9 h. (D+E) HCT116 cells and
HCT116 cells lacking (D) p53 or (E) p21 expression were treated with nutlin-3 and doxorubicin for 24 and 48 hours, respectively. DMSO- or untreated
cells served as controls. (C+F) Cell cycle distribution of the cells was analyzed by FACS. In case of nutlin-3 treatment DMSO was used as solvent
control.
doi:10.1371/journal.pone.0063187.g001
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in the G1 cell population and lowered fractions in G2/M phases.
However, these small changes in cell cycle distribution are not
sufficient to account for alterations in reporter activity [29].
On the basis of these data we conclude, that the CDK inhibitor
p21WAF1/CIP1 seems to be both necessary and sufficient to reduce
the promoter activity of the KIF23 promoter effectively. Further-
more, we showed that the CHR element is necessary to mediate
this repression.
Expression of both Splice Variants of KIF23 is Regulated
Identically during Cell Cycle Progression and Requires a
CHR in the Promoter
Recently, Seguin and coworkers found expression of KIF23 to
be regulated in a cell cycle-dependent manner in the human
interleukin-2 (IL-2)-dependent Kit 225 T-cell line and in HCT116
cells [6]. We wanted to test for differences in cell cycle-dependent
expression of both splice variants of KIF23. To analyze cell-cycle
dependent expression, we employed normal human foreskin
fibroblasts (HFF) as cell system, because they are non-transformed
cells which can be easily starved by serum deprivation [41]. After
starvation, HFF cells were restimulated to pass synchronously
through the cell cycle. At different points of time after
restimulation RNA and protein were extracted and analyzed. As
displayed in Figures 4A and 4B both splice variants of KIF23 were
regulated essentially synchronously in their mRNA (Fig. 4A) and
protein (Fig. 4B) expression.
Consistently, promoter reporter assays demonstrated that KIF23
promoter activity significantly increased from G0 to G2/M during
the cell cycle. Mutation of the CHR element showed that cell
cycle-dependent promoter activity strictly depends on the intact
CHR (Fig. 4D).
DREAM and MMB Complexes Bind to the CHR Element in
the KIF23 Promoter in vitro
The multi-protein complex DREAM has been shown to be
responsible for repression of cell cycle-dependent genes in G0/G1
[10], whereas in proliferating cells recruitment of the MMB
complex leads to increased expression of these genes [11,13,14].
Recently, Mu¨ller et al. showed that phylogenetically conserved
CHR elements are enriched in promoters binding the DREAM
complex. Specifically, DREAM binding to the CHR of cyclin B2
and Ube2c promoters was demonstrated [8]. Thus, we wondered if
these multi-protein complexes are also recruited to the CHR
element of the KIF23 promoter to regulate its cell cycle-dependent
expression.
To this end, we performed DNA-affinity purification with
biotinylated KIF23 promoter probes and nuclear extracts of
asynchronously growing NIH3T3 cells. Subsequent western blot
analyses revealed that the DREAM components p130 and E2f4 as
well as Lin37, a component of the MuvB core complex, and MMB
complex component B-Myb were able to bind to the Kif23 wild-
type promoter in vitro. In density-arrested cells, a clear increase in
protein expression of DREAM complex components p130 und
Figure 2. KIF23 protein levels are diminished after p53 activation and elevated following p53 knockdown. KIF23, p53 and p21 protein
levels were detected by western blot. GAPDH or b-actin served as loading control. (A) In D53wt or D53mut cells the expression of transgenes was
induced for 9 h. (B+C) Wild-type HCT116 cells (HCT116+/+) or HCT116 cells lacking p53 (HCT116 p532/2) or p21 (HCT116 p212/2) were treated with
(B) doxorubicin for 48 and 72 h or with (C) nutlin-3 for 24 h. DMSO was used as solvent control. (D) Human foreskin fibroblasts (HFF) were mock
transfected or transfected with siRNA targeting p53 and control siRNA, respectively.
doi:10.1371/journal.pone.0063187.g002
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E2F4 was observed and recruitment of these two proteins as well
as Lin37 was increased seemingly. In contrast, MMB complex
component B-myb seemed to be bound only in growing cells, as
hardly any recruitment could be detected in arrested cells (Fig. 5A).
Comparing binding of DREAM components to the CHR mutant
of the KIF23 promoter with nonspecific binding to the unrelated
basal mouse Gapdhs promoter (negative control) revealed that
DREAM recruitment to the KIF23 promoter was reduced to
background level after mutation of the CHR element. The nuclear
transcription factor-Y subunit alpha (NFYA), which is able to bind
to CCAAT-boxes [42] present in numerous cell cycle-regulated
promoters including the KIF23 promoter [6], served as a loading
and binding control. As expected, binding of Nfya was observed
independently of the CHR element (Fig. 5A).
These experiments demonstrate that the DREAM complex is
recruited to the KIF23 promoter in density-arrested cells in vitro,
while the MMB complex only seems to bind to the KIF23
promoter in growing cells. A functional CHR element is essential
for both recruitments.
In vivo Binding of DREAM and MMB Complexes to the
KIF23 Promoter is Cell Cycle-dependent
We assayed cell cycle-dependent binding of DREAM and
MMB complexes to the KIF23 promoter in vivo performing
chromatin immunoprecipitations (ChIPs) in serum-starved (0 h)
and restimulated (22 h) human glioblastoma T98G cells. The
DREAM and MMB complexes have been well-characterized in
this cell line [10,11]. Cell cycle distribution of T98G cells was
tested by FACS analyses illustrating cell cycle arrest in G0 after
serum starvation and enrichment of cells in S and G2/M phases at
22 h hours after restimulation (Fig. 5B). ChIP experiments
revealed that the DREAM component E2F4 was strongly bound
to the KIF23 promoter in G0-arrested cells (0h), supporting data
from the DNA-affinity purification analyses, and was released
from the KIF23 promoter in restimulated T98G cells mainly in S/
G2/M phases (Fig. 5C, left diagram). A small decrease in signal
intensity was observed when analyzing promoter binding of LIN9,
a component of the MuvB core complex. In contrast, an increase
in B-Myb binding could be observed in growing cells in vivo
(Fig. 5C, right diagram). No binding was detected analyzing the
human GAPDHS promoter as negative control (Fig. 5D). Taken
together, our results reveal binding of DREAM and MMB
Figure 3. Repression of KIF23 promoter activity by p53 depends on p21WAF1/CIP1 protein and the CHR element. (A) Schematic
illustration of employed KIF23 promoter constructs relative to the translational start site. (Luc = luciferase) (B) Dual luciferase reporter gene assays
were carried out in HCT116 p532/2 (left) or HCT116 p212/2 (right) cells after cotransfection of p53wt, p53mut, p21wt or p21mut expression
plasmids together with the KIF23 wt promoter construct or a KIF23 promoter construct with mutation of the putative CHR element. Empty firefly
luciferase reporter vector served as vector control. Relative light units (RLU) are displayed.
doi:10.1371/journal.pone.0063187.g003
Repression of KIF23 by p53
PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e63187
complex components to the KIF23 promoter in vitro and in vivo in a
cell cycle-dependent manner.
p53-dependent Binding of DREAM/MMB Complex
Components to the KIF23 Promoter in vivo
Many genes whose expression is repressed by p53 are involved
in cell-cycle control and contribute to p53-induced cell-cycle
arrest. The promoters of a wide range of these target genes were
found to bind DREAM and/or MMB-complexes in order to
regulate their expression in a cell cycle-dependent manner
[8,10,12]. We identified KIF23 as a new p53 target gene and
demonstrated that DREAM and MMB complexes bind to the
CHR element in the KIF23 promoter in a cell cycle-dependent
manner. As we showed that this CHR is also responsible for p53-
dependent regulation of the KIF23 promoter, we next asked
whether differential binding of DREAM and MMB may also
occur in a p53-dependent manner. To this end, we performed
ChIP assays using antibodies against DREAM complex compo-
nents E2F4 and p130, MuvB core complex component LIN9 and
MMB complex component B-Myb. Binding of these four proteins
to the KIF23 promoter in untreated HCT116 cells was compared
with their promoter binding activities in cells treated with
doxorubicin for 48 h to enrich endogenous p53 protein. Stabili-
zation of endogenous wild-type p53 led to a clear increase in E2F4
and p130 binding (Fig. 5E, left diagram), whereas B-Myb binding
significantly decreased (Fig. 5E, right diagram). LIN9 seemed to
bind the KIF23 promoter independently of p53 expression (Fig. 5E,
right diagram). In contrast, no binding of p53 itself to the KIF23
promoter was detected while a very strong binding of p53 to the
p21WAF1/CIP1 promoter could be demonstrated (Fig. 5F). The
GAPDHS promoter served as negative control (Fig. 5G).
As shown in Fig. 1F doxorubicin treatment of HCT116 p53+/+
cells increased the number of cells in G2/M. As a result, a shift
Figure 4. The CHR element mediates cell cycle-dependent expression of KIF23. Human foreskin fibroblasts (HFF) were arrested in G0 by
serum starvation and re-entered the cell cycle after serum addition. Cells were harvested at 0 (G0), 12 (G1), 22 (S) or 26 (G2/M) hours after
restimulation. (A) mRNA levels of KIF23 splice variants were measured separately or with primers detecting both splice variants by real-time RT-PCR.
(B) KIF23 protein levels were detected by western blot with b-actin serving as loading control. (C) Cell cycle distribution of HFF cells was confirmed by
FACS analysis. (D) Dual luciferase reporter gene assays were carried out in serum-starved (G0) and 24 h restimulated (G2/M) NIH3T3 cells. Activities of
wild-type and CHR mutant KIF23 promoter constructs as well as the vector control are displayed as relative light units (RLU). (E) DNA content of
serum-starved and 24 h restimulated NIH3T3 cells was analyzed by FACS.
doi:10.1371/journal.pone.0063187.g004
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from DREAM to MMB complex binding to the KIF23 promoter
would be expected. Instead, the observed increase in DREAM
binding proved the effect of p53 on the KIF23 promoter and
showed that the observations are not only due to the overall
changes in the cell cycle.
In summary, we show that KIF23 gene expression is repressed
by p53 and varies during cell cycle. We provide evidence that the
DREAM complex binds to the CHR element of the KIF23
promoter in a p53- and cell cycle-dependent manner. During cell
cycle progression, DREAM binding is released when E2F4 and
the pocket protein p130 is replaced by B-Myb to form the
activating MMB complex in S/G2/M. In case of cellular stress,
p53 seems to repress KIF23 expression indirectly via induction of
the CDK inhibitor p21WAF1/CIP1 and binding of the DREAM
complex to the KIF23 promoter.
Discussion
Loss or mutation of p53 can lead to impairment of the
centrosome duplication cycle, mitotic spindle abnormality and
cytokinesis failure [43]. Assessing microarray data, Kinesin family
member 23 (KIF23), which is essential for proper completion of
cytokinesis, had been suggested as a potential p53 target gene
earlier [19,37]. However, no further investigations had been
carried out to elucidate this correlation. Here, we demonstrated
that p53 wild-type downregulates expression of KIF23 at both
mRNA and protein levels by regulation of KIF23 promoter
activity. This regulation of KIF23 expression is consistent with the
tumor suppressive function of p53, particularly as recent evidence
indicates that KIF23 could serve as a biomarker for some tumor
entities. Among other regulators of cytokinesis, KIF23 expression
was shown to be upregulated in non-small cell lung cancer and
hepatocellular carcinoma [44,45]. Very recently, expression
analysis also revealed a higher level of KIF23 expression in
glioma tissues compared to normal brain tissue and it was
demonstrated that siRNA-mediated downregulation of KIF23
expression significantly suppressed glioma cell proliferation in vitro
[5].
Two splice variants of KIF23 mRNA have been described
previously [38] which differ from each other in the presence or
absence of exon 18. The longer splice variant, also referred to as
CHO1, contains exon 18, coding for an F-actin interacting
domain. F-actin binding proteins have been shown earlier to be
essential in cytokinesis [46]. However, no differential locations or
activities have been described so far for the two KIF23 splice
variants and our data did not reveal any differential regulation of
both slice variants either (Fig. 1B, 1D and 4A). For this, it has to be
analyzed in further studies, whether there are different roles of
KIF23 splice variants in human.
Several molecular mechanisms for p53-dependent repression of
target genes, including direct and indirect mechanisms, have been
described so far (reviewed in reference [20]). Some reports favour
direct repression of G2/M genes through p53 [47,48]. Others
implicated the p53 target gene p21WAF1/CIP1 and the pocket
proteins p130 and p107 in p53-dependent repression mechanisms
earlier [49–51]. The CDK inhibitor p21WAF1/CIP1 operates
upstream of the RB/E2F pathway. By binding to both the cyclin
and the CDK moieties, p21WAF1/CIP1 inhibits activities of all
cyclin-CDK1/2 complexes as well as cyclin D-CDK4/6 com-
plexes [52]. Thus, specific targets, including the pocket protein
family (RB, p107 and p130), cannot be efficiently phosphorylated
by the CDKs. For example, p130 is phosphorylated at serine 672
by CDK4/6 and subsequently targeted for proteasomal degrada-
tion [53]. Inhibition of cyclin-CDK activities by p21WAF1/CIP1
results in RB-family members remaining in a hypophosphorylated
state bound to E2F transcription factors. Subsequently, accumu-
lation of p130 stabilizes the DREAM complex [54,55].
We showed, in concordance with genome-wide p53 binding
studies [56–58], that p53 does not bind the KIF23 promoter
directly (Fig. 5E, left diagram). Furthermore, we demonstrated
that p21WAF1/CIP1 is not only necessary but also sufficient to
repress expression of KIF23. This strict p21WAF1/CIP1-dependency
could be observed at both mRNA (Fig. 1E) and protein levels
(Fig. 2B and 2C) after stabilization of endogenous wild-type p53
protein in the well-established cell line HCT116 p212/2. In
promoter reporter assays a minor p53-dependent and p21-
independent repression of KIF23 promoter activity was detected
(Fig. 3B). This may be due to non-physiological high levels of p53
protein leading to an additional slight p21-independent repression
of KIF23 promoter activity. However, absence of p21WAF1/CIP1 led
to a significant decrease in p53-dependent repression of KIF23
promoter activity (Fig. 3B, right diagram) in this experiment as
well, supporting the data of strict p21WAF1/CIP1-dependency of
KIF23 repression on mRNA and protein level after stabilization of
endogenous wild-type p53 protein.
Very recently, it could be demonstrated that p53-dependent
downregulation of cyclin B2 expression, which also depends strictly
on p21WAF1/CIP1 expression, is mediated by a switch of MMB to
DREAM complex binding to a conserved CHR element [29]. Our
current data reveal that nearly any repression effect of KIF23
expression was lost after mutation of the CHR element in the
KIF23 gene (Fig. 3B). Different 59-deletion mutants of the KIF23
promoter construct did not lead to a significant change in p53-
responsiveness (data not shown) although several E2F sites have
been described for the KIF23 promoter and a time-dependent
recruitment of E2F1 to the KIF23 promoter was observed [6].
Therefore we conclude that, instead of the E2F sites, the CHR is
the major element mediating p53-dependent repression of KIF23
expression. The quest for the proteins binding to CHR elements
has taken very long. Very recently, Mu¨ller et al. found that the
DREAM complex, consisting of the MuvB core, p130 and E2F4,
can bind to the CHR in the cyclin B2 promoter in resting cells to
repress cyclin B2 transcription, whereas the MMB complex,
consisting of the MuvB core and B-Myb, appears to bind to the
CHR element in proliferating cells to activate gene expression [8].
Figure 5. The DREAM and MMB complexes bind to the CHR in the KIF23 promoter. (A) In vitro analysis of DREAM and MMB protein binding
to the KIF23 wild-type (wt) or the CHR mutant promoter. Nuclear extracts of density-arrested or asynchronously growing NIH3T3 cells were employed
for DNA-affinity purification using biotinylated human KIF23 promoter probes. Binding was tested by western blot analysis using antibodies against
p130, E2f4, Lin37 and B-myb. As a protein binding to all KIF23 probes, Nfya was detected. As a negative control, a fragment of the Gapdhs promoter
was used. (B-D) T98G cells were synchronized by serum starvation and restimulated to re-enter the cell cycle for 22 h. (B) FACS analysis confirmed the
cell cycle distribution. (C) Nuclear extracts were prepared and chromatin immunoprecipitation analysis of DREAM and MMB binding to the human
KIF23 promoter in vivo was performed with antibodies targeting E2F4, LIN9 and B-Myb. As a negative control, a non-targeting rabbit antibody (IgG)
was used. All signals are given relative to the input (**p#0.01; ***p#0.001; n = 4). (D) The GAPDHS promoter served as negative control. (E-G) ChIP
experiments were performed in untreated HCT116 cells or HCT116 cells treated with doxorubicin for 48 h. (E) Binding of p53, p130, E2F4, LIN9 and B-
Myb to the KIF23 promoter was analyzed (*p#0.05; **p#0.01; n.s. not significant; n $ 2) using (F) p21 and (G) GAPDHS promoters as controls.
doi:10.1371/journal.pone.0063187.g005
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While the DREAM complex has been described as a global
repressor of cell cycle genes, the MMB complex primarily targets
many late cell cycle genes and activates their transcription in G2/
M phases [8,11,12,14,59]. In this study we provide evidence for
the first time that the DREAM complex is also able to bind to the
CHR element in the KIF23 promoter in resting cells in vitro
(Fig. 5A) and in vivo (Fig. 5C). This binding occurs in a cell cycle-
dependent manner with DREAM binding being substantially
reduced in proliferating cells. In contrast, in resting cells the MMB
complex hardly is observed at the CHR element of the KIF23
promoter, but a clear DNA binding could be demonstrated in
proliferating cells in vitro (Fig. 5A) and in vivo (Fig. 5C). Binding of
both DREAM and MMB complexes is reduced to background
level after mutation of the CHR in the KIF23 promoter. As the
CHR element was also found to be required for p53-dependent
KIF23 repression, we quantified DREAM/MMB complex binding
depending on p53 wild-type expression. Interestingly, stabilization
of endogenous p53 by treatment of the cells with doxorubicin
seems to be followed by a switch from MMB to DREAM complex
binding, with p130 and E2F4 being recruited while B-Myb was
released from the complex (Fig. 5E).
Regarding the requirement of p21WAF1/CIP1 expression for
proper regulation of KIF23 transcription, we suggest the following
molecular mechanism for p53-dependent repression: In absence of
p53 only marginal amounts of the CDK inhibitor p21WAF1/CIP1
are expressed (Fig. 2B and 2C). Therefore cyclin-CDK complexes
phosphorylate their substrates including B-Myb and the pocket
protein family in a cell cycle-dependent manner [60,61]. In G0/G1
hypophosphorylated p130 and E2F4 are bound to the MuvB core
to form the DREAM complex [14] and transcription of cell cycle
genes, including KIF23, is repressed. DREAM complex assembly is
disrupted in early S phase by CDK4-dependent phosphorylation
of p130 and E2F4 which impedes their binding to the MuvB core
component LIN9 [14]. Simultaneously, association of the MuvB
core with B-Myb is enabled by the cyclin A/CDK2-dependent
phosphorylation of B-Myb [14]. Thereby, transcription of genes
expressed in S phase and mitotis, including KIF23, is initiated [62].
In the presence of p53, induced expression of p21WAF1/CIP1
leads to inhibition of cyclin-CDK complexes so that p130, E2F4
and B-Myb remain hypophosphorylated. Comparable with the
situation in resting cells, hypophosphorylated B-Myb is released
from the MMB complex and the DREAM complex is assembled
by recruiting hypophosphorylated p130 and E2F4 to the MuvB
core [29,54,55]. Binding of the repressing DREAM complex to
the CHR in the KIF23 promoter finally leads to p53-dependent
repression.
It is a remarkable finding that an identical molecular
mechanism utilizing the same DNA element is responsible for
cell cycle-dependent expression as well as for p53-dependent
regulation of KIF23 expression. Recent studies suggest that this
molecular mechanism may be employed as a general mechanism
for p53-dependent transcriptional repression of G2/M genes as for
example cyclin B2 and may contribute to carcinogenesis
[8,29,54,55]. DNA damage has been shown to result in a p53-
dependent binding of p130 and E2F4 to and dissociation of B-
Myb from the MuvB core [55]. Genome wide expression studies
have shown that DREAM/MMB complexes are required for
repression and activation of a cluster of genes essential for entry
into mitosis, spindle assembly and cytokinesis [12,13,63,64], most
of which are bona fide p53 target genes. Recently, the CHR
element was demonstrated to be the relevant DNA element
responsible for DREAM/MMB binding to the promoters of a set
of these genes [8]. This element is well known as the essential
DNA site which confers cell cycle-dependent expression of G2/M
genes [7].
Taken together our results suggest that the molecular mecha-
nisms of both cell cycle-dependent expression and p53-dependent
repression of molecular motor protein KIF23 are carried out by
alternate binding of DREAM and MMB complexes to the CHR
in its promoter. As many p53 target genes were expressed in a cell
cycle-dependent manner, it can be assumed that this may be a
common mechanism for transcriptional downregulation of cell
cycle genes by the tumor suppressor protein p53. Further studies
have to be performed in order to solidify this hypothesis. Clearly,
detailed knowledge of molecular mechanisms of p53-dependent
repression is important for the understanding of the process of
tumor suppression and may lead to the development of novel anti-
cancer therapeutics.
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